Joan of Contention 😷Can anyone which pharma know-how tell me: is it safe to take..
💊 Ibuprofen
💊 Decongestant (pseudoephedrine hydrochloride)
💊 Paracetamol
💊 Anti-histamine (any)
..all at the same time?
Asking for me. 🤧
Vietnamnet BOT⚠️ Một phụ nữ ở Trung Quốc phải nhập viện cấp cứu sau khi ăn bưởi trong lúc đang dùng thuốc hạ mỡ máu. Cô gặp triệu chứng mệt mỏi tăng dần, đau nhức cơ bắp nghiêm trọng đến mức không thể đi lại. Bác sĩ cảnh báo: Ăn bưởi sai thời điểm có thể gây tương tác thuốc nguy hiểm! 🍊💊
#SứcKhỏe #TươngTácThuốc #Bưởi #CấpCứu #HealthWarning #DrugInteraction #Grapefruit
https://vietnamnet.vn/an-buoi-khong-dung-thoi-diem-nguoi-phu-nu-phai-di-cap-cuu-2444239.html
Akash Joseph
CharyouTree
Luis M. RochaSo happy this NLM-NIH sponsored work with @alfonsovalencia , @jonsv89, Rion Correia et al is out @BMCMedicine!
We study #DrugInteraction #polypharmacy with longitudinal #DataScience and #NetworkMedicine study of #EHR revealing #gender #age #bias in #health.
https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-024-03384-1
Prevalence and differences in the co-administration of drugs known to interact: an analysis of three distinct and large populations - BMC Medicine
Background The co-administration of drugs known to interact greatly impacts morbidity, mortality, and health economics. This study aims to examine the drug–drug interaction (DDI) phenomenon with a large-scale longitudinal analysis of age and gender differences found in drug administration data from three distinct healthcare systems. Methods This study analyzes drug administrations from population-wide electronic health records in Blumenau (Brazil; 133 K individuals), Catalonia (Spain; 5.5 M individuals), and Indianapolis (USA; 264 K individuals). The stratified prevalences of DDI for multiple severity levels per patient gender and age at the time of administration are computed, and null models are used to estimate the expected impact of polypharmacy on DDI prevalence. Finally, to study actionable strategies to reduce DDI prevalence, alternative polypharmacy regimens using drugs with fewer known interactions are simulated. Results A large prevalence of co-administration of drugs known to interact is found in all populations, affecting 12.51%, 12.12%, and 10.06% of individuals in Blumenau, Indianapolis, and Catalonia, respectively. Despite very different healthcare systems and drug availability, the increasing prevalence of DDI as patients age is very similar across all three populations and is not explained solely by higher co-administration rates in the elderly. In general, the prevalence of DDI is significantly higher in women — with the exception of men over 50 years old in Indianapolis. Finally, we show that using proton pump inhibitor alternatives to omeprazole (the drug involved in more co-administrations in Catalonia and Blumenau), the proportion of patients that are administered known DDI can be reduced by up to 21% in both Blumenau and Catalonia and 2% in Indianapolis. Conclusions DDI administration has a high incidence in society, regardless of geographic, population, and healthcare management differences. Although DDI prevalence increases with age, our analysis points to a complex phenomenon that is much more prevalent than expected, suggesting comorbidities as key drivers of the increase. Furthermore, the gender differences observed in most age groups across populations are concerning in regard to gender equity in healthcare. Finally, our study exemplifies how electronic health records’ analysis can lead to actionable interventions that significantly reduce the administration of known DDI and its associated human and economic costs.
My latest op-ed is about #polipharmacy #druginteraction, which are higher in Portugal than almost everywhere else in Europe, and how #datascience could help. #dataforgood #health #publichealth
Salvo FedeleUn consiglio ai miei colleghi che in questo periodo hanno mille incertezze soprattutto durante la co-somministrazione di Paxlovid agli anziani. C'è un database che a livello internazionale viene considerato la massima autorità sulle interazioni e le co-somministrazioni di tutti i farmaci anti-C19.
Inseritelo tra i preferiti del vostro browser: è di facilissima consultazione ed è a libero accesso
